The Role of Pregnancy-induced Gallbladder Dysmotility in

Status Completed

Clinical Trial Summary

The primary aim of the study is to evaluate postprandial gallbladder emptying and plasma concentrations of the glucose-lowering and satiety-promoting gut hormone glucagon-like peptide 1 (GLP-1) during third trimester of pregnancy in women with gestational diabetes mellitus (GDM) compared with age and body mass index (BMI)-matched pregnant control women with normal glucose tolerance (NGT).

Clinical Trial Description

Gestational diabetes mellitus (GDM) defined as glucose intolerance first detected during pregnancy is a strong predictor of future type 2 diabetes. Patients with GDM exhibit severely reduced postprandial responses of the insulinotropic and satiety-promoting gut hormone glucagon-like peptide 1 (GLP-1), which normalise alongside remission of GDM after delivery. Ingested nutrients and bile acids constitute potent stimulators of GLP-1 secretion. Reduced postprandial GLP-1 responses likely contribute to the pathophysiology of GDM, but the mechanisms are unknown. Based on previous studies studying gallbladder emptying during pregnancy, we hypothesize that reduced postprandial GLP-1 responses in GDM is due to incomplete gallbladder emptying during third trimester. If our hypothesis proves right, reduced gallbladder emptying and ensuing attenuation of postprandial GLP-1 secretion will constitute an obvious and druggable target for the treatment of GDM. Fifteen women with gestational diabetes mellitus and 15 age and body mass index (BMI)-matched pregnant women with normal glucose tolerance will be enrolled in the study. For each subject, the study encompasses one screening visit and two experimental days; one during third trimester of pregnancy and one 3-9 months post partum. On experimental days, a standardised liquid mixed meal test (added 1.5 g of paracetamol for evaluation of gastric emptying according to paracetamol absorption) with repeated ultrasonographic gallbladder scans and blood samples will be performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04108065
Study type	Observational
Source	University Hospital, Gentofte, Copenhagen
Contact
Status	Completed
Phase
Start date	October 2, 2019
Completion date	October 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06099574` - A Study on the Oral Health Status of Pregnant Women With Gestational Diabetes and Its Correlation With Oral Flora
Completed	`NCT02890693` - Improving Cardio-metabolic and Mental Health in Women With Gestational Diabetes Mellitus and Their Offspring	N/A
Completed	`NCT02744300` - Balance After Baby Intervention for Women With Recent Gestational Diabetes	N/A
Completed	`NCT02384226` - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Completed	`NCT02436551` - Gestational Diabetes in Central Asia: Prevalence and Management
Recruiting	`NCT02275845` - Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus	Phase 3
Recruiting	`NCT04621396` - The Next Generation Longitudinal Birth Cohort Diabetes Study
Completed	`NCT01916694` - Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus	N/A
Completed	`NCT01931280` - A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring	N/A
Not yet recruiting	`NCT01637727` - Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women	N/A
Completed	`NCT01565564` - Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes	N/A
Recruiting	`NCT00550979` - Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk	N/A
Completed	`NCT00460018` - Diet, Exercise, and Breastfeeding Intervention Program for Women With Gestational Diabetes (DEBI Trial)	Phase 2
Not yet recruiting	`NCT04915716` - Effect of Fasting Time Before Cesarean Section on Neonatal Blood Glucose in Pregnant Women With Gestational Diabetes Mellitus
Completed	`NCT04422821` - Flash Glucose Monitoring in Gestational Diabetes Mellitus: Study Protocol for a Randomized Controlled Trial	N/A
Recruiting	`NCT04369313` - Effect of DCC on Neonatal Jaundice and Blood Gas Analysis in Infants Born to GDM Mothers	N/A
Recruiting	`NCT05348863` - SPARK- a Digital Platform to Improve Self-management of Gestational Diabetes	N/A
Recruiting	`NCT04272840` - The Impact of Glycemic Index Education on Lowering Dietary GI in Gestational Diabetes Mellitus	N/A
Completed	`NCT02588729` - A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With GDM - RCT	N/A
Completed	`NCT01922791` - Nutrition and Pregnancy Intervention Study	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Role of Pregnancy-induced Gallbladder Dysmotility in the Pathophysiology of Gestational Diabetes Mellitus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms